Does the media favor GEHC or SOLV?

In the previous week, GE HealthCare Technologies had 5 more articles in the media than Solventum. MarketBeat recorded 12 mentions for GE HealthCare Technologies and 7 mentions for Solventum. Solventum's average media sentiment score of 1.32 beat GE HealthCare Technologies' score of 0.78 indicating that Solventum is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GE HealthCare Technologies 3 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solventum 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend SOLV or PHG?

Solventum presently has a consensus target price of $83.67, suggesting a potential upside of 7.98%. Given Solventum's stronger consensus rating and higher possible upside, equities research analysts plainly believe Solventum is more favorable than Koninklijke Philips. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Solventum 1 Sell rating(s) 6 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.43 Koninklijke Philips 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer SOLV or PHG?

In the previous week, Solventum had 5 more articles in the media than Koninklijke Philips. MarketBeat recorded 7 mentions for Solventum and 2 mentions for Koninklijke Philips. Solventum's average media sentiment score of 1.32 beat Koninklijke Philips' score of 0.00 indicating that Solventum is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solventum 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Koninklijke Philips 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, SOLV or ZBH?

Solventum has higher revenue and earnings than Zimmer Biomet. Solventum is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solventum $8.33B 1.61 $1.56B $8.16 9.50 Zimmer Biomet $8.23B 2.21 $705.20M $3.85 24.44

Does the media prefer SOLV or ZBH?

In the previous week, Zimmer Biomet had 4 more articles in the media than Solventum. MarketBeat recorded 11 mentions for Zimmer Biomet and 7 mentions for Solventum. Solventum's average media sentiment score of 1.32 beat Zimmer Biomet's score of 1.16 indicating that Solventum is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solventum 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zimmer Biomet 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, SOLV or SNN?

Solventum has higher revenue and earnings than Smith & Nephew SNATS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solventum $8.33B 1.61 $1.56B $8.16 9.50 Smith & Nephew SNATS $6.16B 2.13 $625M N/A N/A

Does the media prefer SOLV or SNN?

In the previous week, Solventum had 3 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 7 mentions for Solventum and 4 mentions for Smith & Nephew SNATS. Solventum's average media sentiment score of 1.32 beat Smith & Nephew SNATS's score of 0.76 indicating that Solventum is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solventum 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Smith & Nephew SNATS 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, SOLV or PEN?

Solventum has higher revenue and earnings than Penumbra. Solventum is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solventum $8.33B 1.61 $1.56B $8.16 9.50 Penumbra $1.45B 8.62 $177.69M $4.34 73.41

Is SOLV or PEN more profitable?

Solventum has a net margin of 17.33% compared to Penumbra's net margin of 11.76%. Solventum's return on equity of 23.51% beat Penumbra's return on equity. Company Net Margins Return on Equity Return on Assets Solventum 17.33% 23.51% 7.63% Penumbra 11.76% 10.87% 8.45%

Does the media prefer SOLV or PEN?

In the previous week, Solventum had 4 more articles in the media than Penumbra. MarketBeat recorded 7 mentions for Solventum and 3 mentions for Penumbra. Solventum's average media sentiment score of 1.32 beat Penumbra's score of 0.00 indicating that Solventum is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solventum 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Penumbra 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Solventum (SOLV) Competitors

$77.48 +0.78 (+1.02%)

Closing price 07/13/2026 03:59 PM Eastern

Extended Trading

$77.46 -0.03 (-0.03%)

As of 07/13/2026 06:18 PM Eastern

Compare

SOLV vs. GEHC, PHG, ZBH, SNN, and PEN

Should you buy Solventum stock or one of its competitors? MarketBeat compares Solventum with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Solventum include GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), Zimmer Biomet (ZBH), Smith & Nephew SNATS (SNN), and Penumbra (PEN). These companies are all part of the "medical equipment" industry.

How does Solventum compare to GE HealthCare Technologies?

GE HealthCare Technologies (NASDAQ:GEHC) and Solventum (NYSE:SOLV) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

Solventum has a net margin of 17.33% compared to GE HealthCare Technologies' net margin of 9.10%. Solventum's return on equity of 23.51% beat GE HealthCare Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GE HealthCare Technologies	9.10%	20.46%	5.73%
Solventum	17.33%	23.51%	7.63%

GE HealthCare Technologies currently has a consensus target price of $79.48, suggesting a potential upside of 21.69%. Solventum has a consensus target price of $83.67, suggesting a potential upside of 7.98%. Given GE HealthCare Technologies' stronger consensus rating and higher possible upside, research analysts clearly believe GE HealthCare Technologies is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GE HealthCare Technologies	0 Sell rating(s)	10 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.50
Solventum	1 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.43

82.1% of GE HealthCare Technologies shares are owned by institutional investors. 0.4% of GE HealthCare Technologies shares are owned by insiders. Comparatively, 0.2% of Solventum shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

GE HealthCare Technologies has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market. Comparatively, Solventum has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market.

GE HealthCare Technologies has higher revenue and earnings than Solventum. Solventum is trading at a lower price-to-earnings ratio than GE HealthCare Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GE HealthCare Technologies	$20.63B	1.44	$2.08B	$4.18	15.62
Solventum	$8.33B	1.61	$1.56B	$8.16	9.50

In the previous week, GE HealthCare Technologies had 5 more articles in the media than Solventum. MarketBeat recorded 12 mentions for GE HealthCare Technologies and 7 mentions for Solventum. Solventum's average media sentiment score of 1.32 beat GE HealthCare Technologies' score of 0.78 indicating that Solventum is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GE HealthCare Technologies	3 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solventum	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

GE HealthCare Technologies beats Solventum on 10 of the 16 factors compared between the two stocks.

How does Solventum compare to Koninklijke Philips?

Solventum (NYSE:SOLV) and Koninklijke Philips (NYSE:PHG) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

13.7% of Koninklijke Philips shares are held by institutional investors. 0.2% of Solventum shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Solventum has higher earnings, but lower revenue than Koninklijke Philips. Solventum is trading at a lower price-to-earnings ratio than Koninklijke Philips, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.33B	1.61	$1.56B	$8.16	9.50
Koninklijke Philips	$20.17B	1.33	$1.01B	$1.17	23.36

Solventum has a net margin of 17.33% compared to Koninklijke Philips' net margin of 5.49%. Solventum's return on equity of 23.51% beat Koninklijke Philips' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solventum	17.33%	23.51%	7.63%
Koninklijke Philips	5.49%	13.51%	5.48%

Solventum presently has a consensus target price of $83.67, suggesting a potential upside of 7.98%. Given Solventum's stronger consensus rating and higher possible upside, equities research analysts plainly believe Solventum is more favorable than Koninklijke Philips.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.43
Koninklijke Philips	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Solventum has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market. Comparatively, Koninklijke Philips has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market.

In the previous week, Solventum had 5 more articles in the media than Koninklijke Philips. MarketBeat recorded 7 mentions for Solventum and 2 mentions for Koninklijke Philips. Solventum's average media sentiment score of 1.32 beat Koninklijke Philips' score of 0.00 indicating that Solventum is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solventum	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Koninklijke Philips	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Solventum beats Koninklijke Philips on 12 of the 16 factors compared between the two stocks.

How does Solventum compare to Zimmer Biomet?

Solventum (NYSE:SOLV) and Zimmer Biomet (NYSE:ZBH) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Solventum has a net margin of 17.33% compared to Zimmer Biomet's net margin of 9.05%. Solventum's return on equity of 23.51% beat Zimmer Biomet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solventum	17.33%	23.51%	7.63%
Zimmer Biomet	9.05%	13.24%	7.28%

In the previous week, Zimmer Biomet had 4 more articles in the media than Solventum. MarketBeat recorded 11 mentions for Zimmer Biomet and 7 mentions for Solventum. Solventum's average media sentiment score of 1.32 beat Zimmer Biomet's score of 1.16 indicating that Solventum is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solventum	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zimmer Biomet	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Solventum presently has a consensus price target of $83.67, indicating a potential upside of 7.98%. Zimmer Biomet has a consensus price target of $102.33, indicating a potential upside of 8.76%. Given Zimmer Biomet's higher probable upside, analysts clearly believe Zimmer Biomet is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.43
Zimmer Biomet	3 Sell rating(s)	13 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.25

Solventum has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market. Comparatively, Zimmer Biomet has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market.

Solventum has higher revenue and earnings than Zimmer Biomet. Solventum is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.33B	1.61	$1.56B	$8.16	9.50
Zimmer Biomet	$8.23B	2.21	$705.20M	$3.85	24.44

88.9% of Zimmer Biomet shares are owned by institutional investors. 0.2% of Solventum shares are owned by insiders. Comparatively, 1.3% of Zimmer Biomet shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Solventum beats Zimmer Biomet on 9 of the 16 factors compared between the two stocks.

How does Solventum compare to Smith & Nephew SNATS?

Solventum (NYSE:SOLV) and Smith & Nephew SNATS (NYSE:SNN) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

Solventum currently has a consensus target price of $83.67, indicating a potential upside of 7.98%. Smith & Nephew SNATS has a consensus target price of $30.93, indicating a potential downside of 0.49%. Given Solventum's stronger consensus rating and higher probable upside, analysts plainly believe Solventum is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.43
Smith & Nephew SNATS	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17

Solventum has a net margin of 17.33% compared to Smith & Nephew SNATS's net margin of 0.00%. Solventum's return on equity of 23.51% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solventum	17.33%	23.51%	7.63%
Smith & Nephew SNATS	N/A	N/A	N/A

Solventum has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market.

Solventum has higher revenue and earnings than Smith & Nephew SNATS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.33B	1.61	$1.56B	$8.16	9.50
Smith & Nephew SNATS	$6.16B	2.13	$625M	N/A	N/A

In the previous week, Solventum had 3 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 7 mentions for Solventum and 4 mentions for Smith & Nephew SNATS. Solventum's average media sentiment score of 1.32 beat Smith & Nephew SNATS's score of 0.76 indicating that Solventum is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solventum	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Smith & Nephew SNATS	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

25.6% of Smith & Nephew SNATS shares are owned by institutional investors. 0.2% of Solventum shares are owned by company insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Solventum beats Smith & Nephew SNATS on 11 of the 14 factors compared between the two stocks.

How does Solventum compare to Penumbra?

Solventum (NYSE:SOLV) and Penumbra (NYSE:PEN) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

Solventum has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market. Comparatively, Penumbra has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market.

88.9% of Penumbra shares are owned by institutional investors. 0.2% of Solventum shares are owned by insiders. Comparatively, 2.9% of Penumbra shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Solventum has a net margin of 17.33% compared to Penumbra's net margin of 11.76%. Solventum's return on equity of 23.51% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solventum	17.33%	23.51%	7.63%
Penumbra	11.76%	10.87%	8.45%

Solventum has higher revenue and earnings than Penumbra. Solventum is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.33B	1.61	$1.56B	$8.16	9.50
Penumbra	$1.45B	8.62	$177.69M	$4.34	73.41

In the previous week, Solventum had 4 more articles in the media than Penumbra. MarketBeat recorded 7 mentions for Solventum and 3 mentions for Penumbra. Solventum's average media sentiment score of 1.32 beat Penumbra's score of 0.00 indicating that Solventum is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solventum	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Penumbra	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Solventum presently has a consensus price target of $83.67, indicating a potential upside of 7.98%. Penumbra has a consensus price target of $360.33, indicating a potential upside of 13.09%. Given Penumbra's higher possible upside, analysts plainly believe Penumbra is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.43
Penumbra	1 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.11

Summary

Solventum beats Penumbra on 9 of the 16 factors compared between the two stocks.

Get Solventum News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SOLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SOLV vs. The Competition

Export

Metric	Solventum	Medical Services Industry	Medical Sector	NYSE Exchange
Market Cap	$13.28B	$9.60B	$7.05B	$23.46B
Dividend Yield	N/A	1.62%	2.68%	4.02%
P/E Ratio	9.50	26.00	27.15	31.08
Price / Sales	1.61	17.40	587.92	19.77
Price / Cash	8.53	14.81	29.22	18.64
Price / Book	2.66	6.05	10.75	4.77
Net Income	$1.56B	$177.20M	$3.58B	$1.06B
7 Day Performance	1.63%	-2.07%	-2.07%	-0.23%
1 Month Performance	-1.74%	6.96%	3.31%	-0.11%
1 Year Performance	4.59%	11.42%	26.35%	16.46%

Solventum Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SOLV Solventum	3.9393 of 5 stars	$77.48 +1.0%	$83.67 +8.0%	+5.1%	$13.28B	$8.33B	9.50	20,000	Positive News Analyst Forecast
GEHC GE HealthCare Technologies	4.9399 of 5 stars	$64.84 -1.1%	$80.20 +23.7%	-13.1%	$29.82B	$20.63B	15.51	54,000	Analyst Forecast
PHG Koninklijke Philips	1.87 of 5 stars	$28.17 +1.6%	N/A	+13.8%	$27.27B	$20.17B	24.14	65,340
ZBH Zimmer Biomet	3.5278 of 5 stars	$89.75 +2.6%	$102.70 +14.4%	+0.2%	$16.92B	$8.23B	23.31	17,000	Options Volume
SNN Smith & Nephew SNATS	2.0173 of 5 stars	$30.53 +0.9%	$30.93 +1.3%	+2.6%	$12.86B	$6.16B	N/A	16,988	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:SOLV) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Solventum (SOLV) Competitors

SOLV vs. GEHC, PHG, ZBH, SNN, and PEN

How does Solventum compare to GE HealthCare Technologies?

Summary

How does Solventum compare to Koninklijke Philips?

Summary

How does Solventum compare to Zimmer Biomet?

Summary

How does Solventum compare to Smith & Nephew SNATS?

Summary

How does Solventum compare to Penumbra?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SOLV vs. The Competition

Solventum Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Solventum (SOLV) Competitors

SOLV vs. GEHC, PHG, ZBH, SNN, and PEN

How does Solventum compare to GE HealthCare Technologies?

Is GEHC or SOLV more profitable?

Do analysts recommend GEHC or SOLV?

Do institutionals & insiders hold more shares of GEHC or SOLV?

Which has more risk & volatility, GEHC or SOLV?

Which has higher valuation and earnings, GEHC or SOLV?

Does the media favor GEHC or SOLV?

Summary

How does Solventum compare to Koninklijke Philips?

Do insiders and institutionals believe in SOLV or PHG?

Which has higher earnings and valuation, SOLV or PHG?

Is SOLV or PHG more profitable?

Do analysts recommend SOLV or PHG?

Which has more volatility and risk, SOLV or PHG?

Does the media prefer SOLV or PHG?

Summary

How does Solventum compare to Zimmer Biomet?

Is SOLV or ZBH more profitable?

Does the media prefer SOLV or ZBH?

Do analysts prefer SOLV or ZBH?

Which has more risk & volatility, SOLV or ZBH?

Which has preferable valuation and earnings, SOLV or ZBH?

Do institutionals & insiders believe in SOLV or ZBH?

Summary

How does Solventum compare to Smith & Nephew SNATS?

Do analysts prefer SOLV or SNN?

Is SOLV or SNN more profitable?

Which has more volatility & risk, SOLV or SNN?

Which has stronger earnings & valuation, SOLV or SNN?

Does the media prefer SOLV or SNN?

Do institutionals and insiders believe in SOLV or SNN?

Summary

How does Solventum compare to Penumbra?

Which has more volatility and risk, SOLV or PEN?

Do institutionals and insiders have more ownership in SOLV or PEN?

Is SOLV or PEN more profitable?

Which has higher earnings and valuation, SOLV or PEN?

Does the media prefer SOLV or PEN?

Do analysts recommend SOLV or PEN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SOLV vs. The Competition

Solventum Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools